Form 4: Tandem Diabetes CTO Boosts Stake via ESPP, RSU Vesting

Tandem Diabetes Care Inc.'s Chief Technology Officer, Rick Carpenter, reported multiple transactions including stock acquisitions through an employee plan and RSU vesting, alongside tax-related share dispositions.

Summary

• Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), reported several transactions on November 17, 2025.
• Acquired 339 shares of common stock at a price of $15.59 per share through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP).
• Acquired 1,437 shares of common stock at a price of $0 upon the vesting of Restricted Stock Units (RSUs) awarded on May 25, 2023.
• Disposed of 730 shares of common stock at $18.61 per share to satisfy tax withholding requirements related to the vesting of RSUs.
• Acquired an additional 897 shares of common stock at a price of $0 upon the vesting of RSUs awarded on May 23, 2024.
• Disposed of 456 shares of common stock at $18.61 per share to satisfy tax withholding requirements related to the vesting of RSUs.
• Following these transactions, Mr. Carpenter directly beneficially owns 24,053 shares of common stock.
• Remaining derivative securities include 2,874 Restricted Stock Units from the May 25, 2023 award and 5,384 Restricted Stock Units from the May 23, 2024 award.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the Chief Technology Officer acquired shares through an employee plan and received shares from RSU vesting, indicating continued alignment with shareholder interests. However, the disposition of shares for tax purposes is a routine event and does not reflect a negative outlook on the company.

Positives

• The Chief Technology Officer acquired 339 shares of common stock through the company's Employee Stock Purchase Plan, indicating continued investment in the company.
• The vesting of 1,437 and 897 Restricted Stock Units (RSUs) at a $0 exercise price represents a non-cash gain for the officer and demonstrates the company's commitment to long-term incentive plans for its executives.

Negatives

• A total of 1,186 shares (730 + 456) were disposed of to cover tax withholding obligations on RSU vesting, which reduces the officer's direct beneficial ownership of common stock.

Future Outlook

Future vesting schedules for Restricted Stock Units indicate that additional shares will vest in eight equal quarterly installments following the initial 33% vesting on May 15, 2024 (for the 2023 award) and May 15, 2025 (for the 2024 award).

Industry Context

This Form 4 filing details routine insider transactions for an executive at a medical device company specializing in diabetes care. Such filings are common across all industries and reflect standard compensation and employee stock purchase plan activities, rather than specific industry trends.

Related Party Transactions

• Acquisition of common stock through the Tandem Diabetes Care Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP).
• Vesting of Restricted Stock Units (RSUs) awarded under the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive may be viewed positively as it aligns management's interests with those of shareholders, though the net change is relatively small.
• Employees: The transactions reflect the operation of employee stock purchase and long-term incentive plans, which are standard components of executive compensation.

Next Steps

• Continued vesting of Restricted Stock Units from the May 25, 2023 award in eight equal quarterly installments following May 15, 2024.
• Continued vesting of Restricted Stock Units from the May 23, 2024 award in eight equal quarterly installments following May 15, 2025.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Transaction, Rick Carpenter, Chief Technology Officer, Employee Stock Purchase Plan, ESPP, Restricted Stock Units, RSU Vesting, Stock Acquisition, Tax Withholding